Active Biotech: Positive Phase I Results

Research Note

2023-01-30

08:52

Redeye raises its Base Case slightly following the positive conclusion of the phase I trial with laquinimod.

Richard Ramanius

Redeye raises its Base Case to SEK3.0 (2.8) as the phase I trial of the new eye drop formulation of laquinimod was successful. Laquinimod is being developed as a treatment for inflammatory eye diseases, in particular uveitis. The full results will be published during H1 2023. Laquinimod's safe profile as an oral treatment has already been established in earlier trials, so we expected the new eye drop formulation to be safe (by assuming a probability of success of phase I of 90%). The next step will be a phase II trial in which laquinimod is tested on patients. We await information about the design and funding of this trial.

Disclosures and disclaimers